Jubilant Pharmova Peer Comparison

NSE: JUBLPHARMA | BSE: 530019

₹959.80

₹22.80 (2.43%)

As on 27-Oct-2026IST

Market cap

₹15,223 Cr

Revenue (TTM)

₹8,608 Cr

P/E Ratio

43.2

P/B Ratio

2.1

Div. Yield

0.5 %

Edit

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Market cap (₹ Cr)	15,223	30,629	31,066	26,421	25,078
Revenue (₹ Cr)	8,608	3,564	1,593	5,155	1,936
Net Profit (₹ Cr)	351.60	414.00	438.64	674.76	288.22
Net Margin (%)	4.05	11.23	27.16	11.86	14.79
RoE (%)	5.68	8.38	25.02	9.03	29.77
Price to Earnings	43.24	74.89	70.74	--	87.01
Price-To-Book	2.14	6.08	18.00	3.30	18.68

Income Statement (₹ Cr)

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Operating Revenue	8,608.30	3,564.00	1,592.52	9,205.28	1,935.80
Total Income	8,682.20	3,686.00	1,615.23	9,449.59	1,948.58
Total Expenditure	7,390.10	2,792.00	969.32	8,195.15	1,485.56
EBITDA	1,218.20	772.00	623.20	1,010.13	450.24
Depreciation	469.60	226.00	41.96	857.51	50.83
EBIT	748.60	546.00	581.24	152.62	399.41
Interest	217.00	217.00	4.21	342.73	40.84
Other Income	73.90	122.00	22.71	244.31	12.78
Exceptional Items	-59.20	12.00	0.00	-216.88	0.00
Profit before Tax	546.30	463.00	599.74	-162.68	371.35
Provision for Tax	194.70	49.00	161.10	209.13	83.14
Profit after Tax	351.60	414.00	438.64	-371.81	288.22

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Shareholder's Funds	7,092.80	4,940.00	1,857.45	8,142.24	1,288.82
Minority Interest	0.70	-5.00	0.51	0.00	0.00
Non-Current Liabilities	5,888.20	1,712.00	47.15	5,213.99	202.03
Current Liabilities	2,538.90	1,622.00	253.37	5,158.51	835.87
Total Liabilities	15,272.00	8,578.00	1,983.96	17,723.32	2,326.71

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Non-Current Assets	10,892.60	5,343.00	1,132.12	10,687.30	519.60
Current Assets	4,109.30	2,606.00	1,012.00	7,253.65	1,681.81
Total Assets	15,272.00	8,578.00	1,983.96	17,723.32	2,326.71
Total Debt*	3,219.50	2,125.00	26.49	5,495.48	259.37
Net Current Assets	1,570.40	984.00	758.64	2,095.14	845.94
Contingent Liabilities	419.40	768.26	17.25	95.72	19.09

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Cash From Operating Activities	1,226.80	390.00	292.17	1,652.60	205.05
Cash Flow from Investing Activities	-1,260.00	-241.00	-265.94	-826.03	-409.72
Cash from Financing Activities	94.90	-54.00	4.10	-38.98	283.07
Net Cash Inflow / Outflow	61.70	95.00	30.33	787.59	78.39

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
ROCE (%)	8.69	6.79	32.42	1.24	29.22
ROE (%)	5.68	8.38	25.02	-3.83	29.77
ROA (%)	2.49	4.94	22.40	-2.14	24.77
EBIT Margin (%)	8.70	15.32	36.50	1.66	20.63
Net Margin (%)	4.05	11.23	27.16	-3.93	14.79
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Revenue Growth (%)	16.27	18.37	45.18	0.78	46.65
EBIT Growth (%)	-10.43	252.26	115.51	-70.53	62.13
Net Profit Growth (%)	-23.16	377.85	95.80	-1,383.43	89.49
EPS Growth (%)	-20.22	1,001.33	63.29	-484.84	78.60
Book Value Growth (%)	13.36	13.47	26.03	0.33	144.31

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Price / Earnings	39.16	76.86	70.74	-84.44	85.67
Price / Book Value	2.14	6.08	18.00	3.30	18.68
Dividend Yield (%)	0.52	0.00	0.07	0.00	0.10
EV/EBITDA	14.10	41.57	49.53	30.25	55.51
Market Cap (₹ Cr)	12,899.62	19,071.62	20,944.75	18,108.89	12,753.19

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debt to Equity	0.42	0.31	0.02	0.55	0.11
Short term debt to equity ratio	0.02	0.09	0.00	0.09	0.05
Current Ratio	1.62	1.61	3.99	1.41	2.01
Quick Ratio	1.13	1.06	2.89	0.77	1.14
Interest Coverage	3.52	3.13	143.52	0.53	10.09

	Jubilant Pharmova	Wockhardt	Acutaas Chemicals	Piramal Pharma	Rubicon Research
Debtors to sales (%)	12.43	16.50	22.50	24.48	26.28
Asset Turnover	0.61	0.43	0.81	0.53	1.66
Receivable days	40.92	58.75	88.98	78.20	40.13
Inventory Days	49.26	75.82	56.04	93.30	60.29
Payable days	154.52	186.21	99.95	226.14	232.47
Cash Conversion Cycle	-64.33	-51.64	45.07	-54.64	-132.04

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.